| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5681818 | INSMED | Therapeutic uses of human somatomedin carrier proteins |
Oct, 2014
(9 years ago) | |
Iplex is owned by Insmed.
Iplex contains Mecasermin Rinfabate Recombinant.
Iplex has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Iplex are:
- US5681818
Iplex was authorised for market use on 12 December, 2005.
Iplex is available in injectable;subcutaneous dosage forms.
Iplex can be used as a method of using rinfabate recombinant (rhigfbp-3) with mecasermin recombinant (rhigf-1) to promote linear growth in the treatment of primary igf-1 deficiency.
The generics of Iplex are possible to be released after 28 October, 2014.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 12, 2012 |
Drugs and Companies using MECASERMIN RINFABATE RECOMBINANT ingredient
Market Authorisation Date: 12 December, 2005
Treatment: A method of using rinfabate recombinant (rhigfbp-3) with mecasermin recombinant (rhigf-1) to promote linear growth in the treatment of primary igf-1 deficiency
Dosage: INJECTABLE;SUBCUTANEOUS
IPLEX family patents
List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US5681818 | NA | Therapeutic uses of human somatomedin carrier proteins |
May, 2019
(5 years ago) |
Ingredients: MECASERMIN RINFABATE [RDNA ORIGINAL INJECTION]